FrancophonIA/ELRC3.0 huggingface dataset:
English: Do not use the drops with your lenses in. After using the drops wait 15 minutes before putting your lenses back in.
Maltese: Għalhekk il-kuntatt ma' lentijiet ta' kuntatt rotob għandu jiġi evitat għal 15-il minuta wara li jkunu ġew applikati l-qtar għall-għajnejn.
English: • Cystadrops must be brought back at room temperature before the first administration.
Maltese: • Cystadrops għandu jinġieb lura għal temperatura ambjentali qabel l-ewwel amministrazzjoni.
English: Cystinosis is a rare hereditary disease in which the body is unable to remove excess cystine (an amino acid), causing cystine crystals to accumulate in various organs (such as kidney and eyes).
Maltese: Ċistinożi hija marda ereditarja rari li fiha l-ġisem ma jkunx kapaċi jneħħi ċ-ċistina żejda (amino aċidu), li jikkawża l-akkumulazzjoni ta' kristalli ċistina f'diversi organi (bħal pereżempju l-kliewi u lgħajnejn).
English: Administer eye ointments last.
Maltese: Huwa meħtieġ monitoraġġ.
English: How to store Cystadrops
Maltese: X'inhu Cystadrops
English: Cystadrops may be used in paediatric patients from 2 years of age at the same dose as in adults (see section 5.1).
Maltese: Cystadrops jista' jintuża fuq pazjenti pedjatriċi minn sentejn ‘il fuq bl-istess doża tal-adulti (ara sezzjoni 5.1).
English: • After using Cystadrops, press a finger into the corner of your eye by the nose (picture 7), then gently massage your upper eyelid to spread the eye drops over the eye.
Maltese: • Wara li tuża Cystadrops, agħfas saba' fil-kantuniera t'għajnejk ħdejn imnieħrek (stampa 7), imbagħad ġentilment immassaġġja l-parti ta' fuq tal-kappell t'għajnejk biex tferrex il-qtar għall-għajnejn m'għajnejk kollha.
English: The most common adverse reactions are eye pain, ocular hyperaemia, eye pruritus, lacrimation increased, blurred vision or eye irritation.
Maltese: L-iktar reazzjonijiet avversi komuni huma uġigħ fl-għajnejn, iperimija okulari, ħakk fl-għajnejn, żieda fit-tidmigħ, vista mċajpra jew irritazzjoni fl-għajnejn.
English: In case of accidental ingestion, monitoring and symptomatic management of the patient should be implemented.
Maltese: F'każ ta' inġestjoni aċċidentali, għandu jkun hemm monitoraġġ u ġestjoni sintomatika tal-pazjent.
English: 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 85 45 E-mail: mail@emea.europa.eu http://www.emea.europa.eu©EMEA 2008 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged
Maltese: (44-20) 74 18 84 00 Fax (44-20) 74 18 85 45 E-mail: mail@emea.europa.eu http://www.emea.europa.eu©EMEA 2008 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged
English: Medicinal product no longer authorise©EMEA 2008
Maltese: Prodott mediċinali li m'għadux awtorizza©EMEA 2008
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) IONSYS EPAR summary for the public
Maltese: RAPPORT TAL-VALUTAZZJONI PUBBLIKA EWROPEA (EPAR) IONSYS Sommarju ta' l-EPAR għall-pubbliku
English: IONSYS is an iontophoretic transdermal system (ITS), which delivers the active substance, fentanyl hydrochloride, into the body through the skin.
Maltese: IONSYS hija sistema transdermali jontoforetika (ITS), li twassal is-sustanza attiva, fentanyl hydrochloride, għal ġol-ġisem minn ġol-ġilda.
English: What is IONSYS?
Maltese: IONSYS?
English: Fentanyl, the active substance in IONSYS, can be abused.
Maltese: Fentanyl, is-sustanza attiva f'IONSYS, tista' tkun abbużata.
English: The European Commission granted a marketing authorisation valid throughout the European Union for IONSYS to Janssen-Cilag International NV on 24 January 2006.
Maltese: Il-Kummissjoni Ewropea tat l-awtorizzazzjoni għat-tqegħid fis-suq għal IONSYS valida fl-Unjoni Ewropea kollha lil Janssen-Cilag International NV fl-24 ta' Jannar 2006.
English: Why has IONSYS been approved?
Maltese: Għaliex giet approvata IONSYS?
English: It must then be removed by a doctor or nurse.
Maltese: Imbagħad hija għandha titneħħa minn tabib jew infermiera.
English: In three of them, IONSYS was compared with placebo (a transdermal system identical to IONSYS, but from which the medicine could not be released).
Maltese: Fi tlieta minnhom, IONSYS kienet imqabbla ma' plaċebo (sistema transdermali identika għal IONSYS, iżda minn liema ma setgħetx tiġi rilaxxata l-mediċina).
English: IONSYS can be used up to six times in one hour, but for no more than 80 doses within a 24-hour period.
Maltese: IONSYS tista' tintuża sa sitt darbiet f'siegħa, iżda għal mhux aktar minn 80 doża fi żmien perijodu ta' 24 siegħa.
English: Four main studies were performed in about 800 patients after an operation.
Maltese: Saru erba' studji ewlenin f'madwar 800 pazjent wara operazzjoni.
English: The most common side effects with IONSYS (seen in more than 1 patient in 10) are nausea (feeling sick), vomiting, headache and erythema (redness of the skin) at the site of application.
Maltese: L-aktar effetti sekondarji b'IONSYS (dehru f'aktar minn pazjent 1 f'10) huma nawżja (dardir), remettar, uġigħ ta' ras u eritima (ħmura tal-ġilda) fis-sit ta' l-applikazzjoni.
English: The fourth study compared IONSYS to morphine given by injection into a vein, and looked at the number of patients who judged their pain relief as ‘good' or ‘excellent'.
Maltese: Ir-raba' studju qabbel IONSYS ma' morfina mogħtija permezz ta' injezzjoni ġo vina, u studja nnumru ta' pazjenti li qiesu s-serħan mill-uġigħ tagħhom bħala ‘tajjeb' jew ‘eċċellenti'.
English: The effects of IONSYS were first tested in experimental models before being studied in humans.
Maltese: L-effetti ta' IONSYS kienu l-ewwel ittestjati f'mudelli esperimentali qabel ma ġew studjati filbnedmin.
English: The company that makes IONSYS will monitor the key safety risks associated with IONSYS such as overdose, abuse, addiction or misuse, and will provide an educational plan for patients, doctors and healthcare providers, aimed at minimising the risk and supporting the safe and effective use of the medicine.
Maltese: Il-kumpanija li tagħmel IONSYS se tissorvelja r-riskji ta' sigurtà ewlenin assoċjati ma' IONSYS bħalma huma teħid eċċessiv, abbuż, vizzju jew użu ħażin, u se tipprovdi pjan edukattiv għal pazjenti, tobba u għal dawk li jipprovdu kura tas-saħħa, immirat li jċekken ir-riskju u jappoġġja l-użu sikur u effettiv tal-mediċina.
English: Fentanyl is derived from opium.
Maltese: Fentanyl huwa imnissel mil-loppju.
English: For the full list of all side effects reported with IONSYS, see the Package Leaflet.
Maltese: Għal-lista sħiħa ta' effetti sekondarji irrapportati b'IONSYS, ara l-Fuljett ta' Tagħrif.
English: What is the risk associated with IONSYS?
Maltese: X'inhu r-riskju assoċjat ma' IONSYS?
English: The Committee for Medicinal Products for Human Use (CHMP) concluded that IONSYS offers potential benefits compared to systems where the pain relief is given via a vein: it is non-invasive, needle-free and pre-programmed, and it can be activated by the patient.
Maltese: Il-Kumitat għall-Prodotti Mediċinali għal Użu mill-Bniedem (CHMP) ikkonkluda li IONSYS toffri benefiċċji potenzjali meta mqabbla ma' sistemi fejn is-serħan ta' l-uġigħ jingħata minn vina: mhijiex invażiva, hija mingħajr labar u ipprogrammata minn qabel, u hija tista' tiġi attivata mill-pazjent.
English: However, the risk with IONSYS is low, as the medicine is for short-term use.
Maltese: Madankollu, ir-riskju b'IONSYS huwa baxx, peress li l-mediċina hija għal użu ta' qasir żmien.
English: When in pain, the patient uses a button on the IONSYS system to start the delivery of a dose of fentanyl (40 micrograms).
Maltese: Meta jkun muġugħ, il-pazjent juża buttuna fuq is-sistema IONSYS biex jingħata doża ta' fentanyl (40 mikrogramma).
English: IONSYS must only be used in hospital, and it must not be used in patients who have respiratory problems (such as breathing difficulties), or heart, liver or kidney problems.
Maltese: IONSYS għandha tintuża biss fl-isptar, u m'għandhiex tintuża f'pazjenti li għandhom problemi respiratorji (bħalma huma diffikultajiet fit-teħid tan-nifs), jew problemi bil-qalb, fwied jew kliewi.
English: Therefore, the Committee decided that IONSYS's benefits are greater than its risks for the management of acute moderate to severe post-operative pain for use in a hospital setting only.
Maltese: Għaldaqstant, il-Kumitat iddeċieda li l-benefiċċji ta' IONSYS huma akbar mir-riskji tagħha għallġestjoni ta' uġigħ akut moderat għal sever ta' wara operazzjoni għal użu f'sitwazzjoni ta' sptar biss.
English: How does IONSYS work?
Maltese: X'inhi IONSYS?
English: These results show that IONSYS has a benefit in controlling pain after an operation.
Maltese: Dawn ir-riżultati juru li IONSYS għandha benefiċċju f'li tikkontrolla l-uġigħ wara operazzjoni.
English: How has IONSYS been studied?
Maltese: Kif ġiet studjata IONSYS?
English: Other information about IONSYS:
Maltese: Tagħrif ieħor dwar IONSYS:
English: 1 bottle + 1 syringe + 1 bottle adapter
Maltese: 1 Flixkun + 1 siringa + 1 adapter talflixkun flixkun (HPDE)
English: Oral solution Oral use
Maltese: Soluzzjoni orali
English: It may harm them, even if their signs of illness are the same as yours.
Maltese: Għadu mhux magħruf l-effett ta' voriconazole fuq erythromycin jew azithromycin.
English: Località Marino del Tronto 63100 Ascoli Piceno (AP) Italy
Maltese: Località Marino del Tronto 63100 Ascoli Piceno (AP) L-Italja
English: Manufacturer Fareva Amboise, Zone Industrielle, 29 route des Industries, 37530 Pocé-sur-Cisse, France.
Maltese: Manifattur Fareva Amboise, Zone Industrielle, 29 route des Industries, 37530 Pocé-sur-Cisse, Franza.
English: Macrolide antibiotics
Maltese: Antibijotiċi macrolide
English: Date of first authorisation: 19 March 2002 Date of latest renewal: 21 February 2012
Maltese: Data ta' l-ewwel awtorizzazzjoni: 19 ta' Marzu 2002 Data ta' l-aħħar tiġdid: 21 ta' Frar 2012
English: • Existing symptomatic arrhythmias.
Maltese: • Arritmiji sintomatiċi eżistenti.
English: Powder for oral suspension 45 g
Maltese: Trab għal suspensjoni orali 45g
English: R-methadone (active) Cmax  31% R-methadone (active) AUC  47% S-methadone Cmax  65% S-methadone AUC  103%
Maltese: R-methadone (attiv) Cmax  31% R-methadone (attiv) AUC  47% S-methadone Cmax  65% S-methadone AUC  103%
English: Interaction table
Maltese: Tabella tal-Interazzjonijiet
English: EUCAST Breakpoints
Maltese: Breakpoints tal-EUCAST
English: • invasive aspergillosis (a type of fungal infection due to Aspergillus sp),
Maltese: • aspergillosis invażiva (tip ta' infezzjoni fungali b'Aspergillus sp),
English: VFEND suspension contains 0.54g sucrose per ml of suspension.
Maltese: Is-suspensjoni VFEND fiha 0.54 g sucrose għal kull ml ta' suspensjoni.
English: Sodium Chloride 9 mg/ml (0.9%) Solution for Injection Compound Sodium Lactate Intravenous Infusion 5% Glucose and Lactated Ringer's Intravenous Infusion 5% Glucose and 0.45% Sodium Chloride Intravenous Infusion 5% Glucose Intravenous Infusion 5% Glucose in 20 mEq Potassium Chloride Intravenous Infusion 0.45% Sodium Chloride Intravenous Infusion 5% Glucose and 0.9% Sodium Chloride Intravenous Infusion
Maltese: Sodium Chloride 9 mg/ml (0.9%) Soluzzjoni għal Injezzjoni Kompożizzjoni ta' Infuzjoni ta' Sodium Lactate għal-gol-vina 5% Glucose u Lactated Ringer's Intravenous Infusion 5% Glucose u 0.45% Infużjoni Ġol-Vini ta' Sodium Chloride 5% Infużjoni Ġol-Vini ta' Glucose 5% Glucose fi 20 mEq ta' Infużjoni Ġol-Vini ta' Potassium Chloride 0.45% Infużjoni Ġol-Vini ta' Sodium Chloride 5% Glucose u 0.9% Infużjoni Ġol-Vini ta' Sodium Chloride
English: Powder for solution for infusion and powder for oral suspension: Fareva Amboise
Maltese: Trab għal soluzzjoni għall-infużjoni u trab għal suspensjoni orali: Fareva Amboise
English: Digoxin (0.25 mg QD) [P-gp substrate]
Maltese: Digoxin (0.25 mg QD) [sustratt ta' P-gp]
English: Silica Colloidal Anhydrous Titanium Dioxide (E171) Xanthan Gum Sodium Citrate Citric Acid Anhydrous Sodium Benzoate (E211) Natural Orange Flavour
Maltese: Silica, Colloidal Anhydrous Titanium Dioxide (E171) Xanthan Gum Sodium Citrate Citric Acid Anhydrous Sodium Benzoate (E211) Togħma ta' Larinġ Naturali
English: • The active substance is voriconazole.
Maltese: • Is-sustanza attiva hi voriconazole.
English: Astemizole, cisapride, pimozide, quinidine and terfenadine [CYP3A4 substrates]
Maltese: Astemizole, cisapride, pimozide, quinidine u terfenadine [sustratti ta' CYP3A]
English: VFEND 200 mg film-coated tablets Each tablet contains 253.675 mg lactose monohydrate.
Maltese: VFEND 200 mg pilloli miksijin b'rita Kull pillola fiha 253.675 mg lactose monohydrate.
English: Marketing Authorisation Holder Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 Bruxelles, Belgium.
Maltese: Id-detentur ta' l-awtorizzazzjoni għat-tqegħid fis-suq Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 Bruxelles, Il-Belġju.
English: Compared to voriconazole 200 mg BID,
Maltese: Ikkumparat ma' voriconazole 200 mg BID,
English: See “Visual impairments” paragraph in section 4.8.
Maltese: Ara l-paragrafu “Indebolimenti viżwali” fis-sezzjoni 4.8.
English: • Non-steroidal anti-inflammatory drugs (e.g., ibuprofen, diclofenac) (used for treating pain and inflammation)
Maltese: • Mediċini anti-infjammatorji non-sterojdali (e.ż., ibuprofen, diclofenac) (użati kontra l-uġigħ u infjammazzjoni)
English: Benzodiazepines (e.g., midazolam, triazolam, alprazolam) [CYP3A4 substrates]
Maltese: Benzodiazepines (e.ż., midazolam, triazolam, alprazolam) [sustratti ta' CYP3A4]
English: Phenytoin Cmax  67% Phenytoin AUC  81% Compared to voriconazole 200 mg BID,
Maltese: Phenytoin Cmax  67% Phenytoin AUC  81% Ikkumparat ma' voriconazole 200 mg BID,
English: Includes akathisia and parkinsonism.
Maltese: Tinkludi akatisja u parkinsoniżmu.
English: Ranitidine (150 mg BID) [increases gastric pH]
Maltese: Ranitidine (150 mg BID) [jżid il-pH gastriku]
English: In an independent published study, Oxycodone Cmax  1.7-fold Oxycodone AUC0-  3.6-fold
Maltese: Fi studju indipendenti ppublikat, Oxycodone Cmax  1.7 darbiet Oxycodone AUC0-  3.6 darbiet
English: • Fluconazole (used for fungal infections)
Maltese: • Fluconazole (użat għal infezzjonijiet fungali)
English: There is limited data on the safety of VFEND in patients with abnormal liver function tests (aspartate transaminase [AST], alanine transaminase [ALT], alkaline phosphatase [ALP], or total bilirubin >5 times the upper limit of normal).
Maltese: Hemm dejta limitata dwar is-sigurtà ta' VFEND f'pazjenti b'testijiet tal-funzjoni tal-fwied mhux normali (aspartate transaminase [AST], alanine transaminase [ALT], alkaline phosphatase [ALP], jew bilirubin totali >5 darbiet il-limitu ta' fuq tan-normal).
English: Film-coating Hypromellose Titanium dioxide (E171) Lactose monohydrate Glycerol triacetate
Maltese: Kisja tar-rita Hypromellose Titanium dioxide (E171) Lactose monohydrate Glycerol triacetate
English: Voriconazole Cmax and AUC ↔
Maltese: Voriconazole Cmax u AUC ↔
English: Methadone (32-100 mg QD) [CYP3A4 substrate]
Maltese: Methadone (32-100 mg QD) [sustratt ta' CYP3A4]
English: Multiple intravenous doses of 3, 4, 6, 7 and 8 mg/kg twice daily and multiple oral doses (using the powder for oral suspension) of 4 mg/kg, 6 mg/kg, and 200 mg twice daily were evaluated in 3 paediatric pharmacokinetic studies.
Maltese: .Dożi multipli filvina ta' 3, 4, 6, 7 u 8 mg/kg darbtejn kuljum u dożi multipli orali (bl-użu tat-trab għas-suspensjoni orali) ta' 4 mg/kg, 6 mg/kg, u 200 mg darbtejn kuljum kienu evalwati fi 3 studji farmakokinetiċi f'pazjenti tfal.
English: Erythromycin (1 g BID) [CYP3A4 inhibitor]
Maltese: Erythromycin (1 g BID) [inibitur ta' CYP3A4]
English: Step 5
Maltese: Punt 5
English: Sulfonylureas (e.g., tolbutamide, glipizide, glyburide) [CYP2C9 substrates]
Maltese: Sulfonylureas (e.ż., tolbutamide, glipizide, glyburide) [sustratti ta' CYP2C9]
English: Statins (e.g., lovastatin) [CYP3A4 substrates]
Maltese: Statins (e.ż., lovastatin) [sustratti ta' CYP3A4]
English: Efavirenz (a non-nucleoside reverse transcriptase inhibitor) [CYP450 inducer; CYP3A4 inhibitor and substrate]
Maltese: Efavirenz (inibittur tan-nonnucleoside reverse transcriptase) [induttur ta' CYP450; inibitur u sustratt ta' CYP3A4]
English: St. John's Wort [CYP450 inducer; Pgp inducer] 300 mg TID (coadministered with voriconazole 400 mg single dose)
Maltese: St John's Wort (fexfiex) [induttur ta' CYP450 ; induttur ta' P-gp] 300 mg TID (mogħti flimkien ma' doża waħda ta' 400 mg voriconazole)
English: Mycophenolic acid Cmax ↔ Mycophenolic acid AUCt ↔
Maltese: Aċidu mikofenoliku Cmax ↔ Aċidu mikofenoliku AUCt ↔
English: • Statins (e.g., atorvastatin, simvastatin) (used for lowering cholesterol)
Maltese: • Statins (e.ż., atorvastatin, simvastatin) (użati biex ibaxxu l-kolesterol)
English: The placeboadjusted mean maximum increases in QTc from baseline after 800, 1200 and 1600 mg of voriconazole were 5.1, 4.8, and 8.2 msec, respectively and 7.0 msec for ketoconazole 800 mg. No subject in any group had an increase in QTc of ≥ 60 msec from baseline.
Maltese: Iż-żidiet massimi medji aġġustati bil-plaċebo fil-QTc mil-linja bażika wara 800, 1200 u 1600 mg ta' voriconazole kienu 5.1, 4.8, u 8.2 msec, rispettivament u 7.0 msec għal ketoconazole 800 mg.
English: Oxycodone (10 mg single dose)
Maltese: Oxycodone (doża waħda ta' 10 mg)
English: The survival rate at Day 180 was 80.0% (32/40) and at 1 year was 70.0% (28/40).
Maltese: 0% (32/40) u massena kienet ta' 70.0% (28/40).
English: Fentanyl (5 g/kg single dose)
Maltese: Fentanyl (doża waħda ta' 5 g/kg)
English: In 10 therapeutic studies, the median for the average and maximum plasma concentrations in individual subjects across the studies was 2425 ng/ml (inter-quartile range 1193 to 4380 ng/ml) and 3742 ng/ml (interquartile range 2027 to 6302 ng/ml), respectively.
Maltese: F'10 studji terapewtiċi, il-punt medjan għal konċentrazzjonijiet medji u massimi fil-plasma f'suġġetti individwali madwar l-istudji kien 2425 ng/ml (medda inter-quartile 1193 sa 4380 ng/ml) u 3742 ng/ml (medda inter-quartile 2027 sa 6302 ng/ml), rispettivament.
English: • Ergot alkaloids (e.g., ergotamine, dihydroergotamine; used for migraine)
Maltese: • Alkalojdi ta' l-ergotina (e.ż., ergotamine, dihydroergotamine; użati għall-emigranja)
English: Mycophenolic acid (1 g single dose) [UDP-glucuronyl transferase substrate]
Maltese: Aċidu mikofenoliku (doża waħda ta' 1 g) [sustratt ta' UDP-glucuronyl transferas]
English: VFEND must not be infused into the same line or cannula concomitantly with other drug infusions, including parenteral nutrition (e.g., Aminofusin 10% Plus).
Maltese: VFEND ma għandux jiġi infuż fl-istess linja jew kannula fl-istess ħin ma' infużjonjiet ta' prodotti mediċinali oħra, inkluż nutriment parenterali (eż Aminofusin 10% Plus).
English: In an independent published study, Voriconazole AUC0-  59%
Maltese: Fi studju indipendenti ppublikat, Voriconazole AUC0-  59%
English: The asterisk (*) indicates a twoway interaction.
Maltese: L-asterisk (*) jindika interazzjoni miż-żewġ naħat.
English: Powder for oral suspension
Maltese: Suspensjoni orali
English: In an independent published study, Sirolimus Cmax  6.6-fold Sirolimus AUC0-  11-fold
Maltese: Fi studju indipendenti ppublikat, Sirolimus Cmax  6.6 darbiet Sirolimus AUC0-  11 il-darba
English: Pharmacokinetic/pharmacodynamic Relationship
Maltese: Relazzjonijiet farmakokinetiċi/farmakodinamiċi
English: MIC breakpoint (mg/L) ≤S (Susceptible) >R (Resistant)
Maltese: MIC breakpoint (mg/L)
English: Frequency categories are expressed as: Very common (1/10); Common (1/100 to 1/10); Uncommon (1/1,000 to 1/100); Rare (1/10,000 to 1/1,000); Very rare (1/10,000); Not known (cannot be estimated from the available data).
Maltese: Komuni ħafna (≥1/10; Komuni (≥1/100 u <1/10); Mhux komuni (≥1/1,000 u <1/100); Rari (≥1/10,000 u <1/1,000);
English: - The other ingredients are sucrose; silica colloidal; titanium dioxide; xanthan gum; sodium citrate; sodium benzoate; citric acid; natural orange flavour.
Maltese: • Is-sustanzi l-oħra huma sucrose; silica, colloidal ; titanium dioxide; xanthan gum; sodium citrate; sodium benzoate; aċidu ċitriku; togħma naturali tal-larinġ.
English: High dose (400 mg BID)
Maltese: Doża għolja (400 mg BID)
English: squamous cell carcinoma*
Maltese: karċinoma fiċ-ċelluli skwamużi*
English: Low dose (100 mg BID)
Maltese: Doża baxxa (100 mg BID)
English: • serious invasive Candida sp. infections when the fungus is resistant to fluconazole (another antifungal medicine),
Maltese: • infezzjonijiet invażivi serji ta' Candida sp. fejn il-fungus huwa reżistenti għal fluconazole (mediċina antifungali oħra),
English: In vitro activity against clinical isolates has been observed for Acremonium spp., Alternaria spp., Bipolaris spp., Cladophialophora spp., and Histoplasma capsulatum, with most strains being inhibited by concentrations of voriconazole in the range 0.05 to 2 µg/ml.
Maltese: Attività in vitro kontra iżolati kliniċi kienet osservata għal Acremonium spp., Alternaria spp., Bipolaris spp., Cladophialophora spp., u Histoplasma capsulatum, bil-maġġoranza tal-forom jiġu mwaqqfa b'konċentrazzjonijiet ta' voriconazole fil-medda ta' 0.05 sa 2 g/ml.
English: Phenytoin [CYP2C9 substrate and potent CYP450 inducer]
Maltese: Phenytoin [sustratt ta' CYP2C9 u induttur qawwi ta' CYP450]
English: Alfentanil (20 μg/kg single dose, with concomitant naloxone)
Maltese: Alfentanil (doża waħda ta' 20 μg/kg, flimkien ma' naloxone)
English: Note: Based on a population pharmacokinetic analysis in 112 immunocompromised paediatric patients aged 2 to <12 years and 26 immunocompromised adolescents aged 12 to <17 years.
Maltese: Nota: Fuq bażi tal-analiżi farmakokinetika tal-popolazzjoni fi 112 pazjenti immunokompromessi tfal ta' bejn 2 u <12-il sena u 26 adoloxxenti immunokompromessi ta' bejn 12 u <17-il sena.
English: • Sulfonylureas (e.g., tolbutamide, glipizide, and glyburide) (used for diabetes)
Maltese: • Sulfonylureas (e.ż., tolbutamide, glipizide, u glyburide) (użati għad-dijabete)
English: Store in a refrigerator (2°C - 8°C).
Maltese: Aħżen fi friġġ (2°C - 8°C ) qabel rikostituzzjoni.
English: Step 4
Maltese: Punt 4
English: Total parenteral nutrition: Total parenteral nutrition (TPN) need not be discontinued when prescribed with VFEND, but does need to be infused through a separate line.
Maltese: Nutrizzjoni parenterali totali: In-nutrizzjoni parenterali totali (TPN) m'hemmx għalfejn tiġi mwaqqfa meta ordnata ma' VFEND, iżda trid tiġi infuża minn linja separata.
English: Immunosuppressants [CYP3A4 substrates]
Maltese: Immunosoppressanti [sustratti ta' CYP3A4]
English: Treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei).
Maltese: Kura ta' infezzjonijiet invażivi serji Candida reżistenti għal fluconazole (fosthom C. krusei).
English: VFEND 50 mg film-coated tablets Each tablet contains 63.42 mg lactose monohydrate.
Maltese: VFEND 50 mg pilloli miksijin b'rita Kull pillolla fiha 63.42 mg lactose monohydrate
English: Ergot alkaloids (e.g., ergotamine and dihydroergotamine) [CYP3A4 substrates]
Maltese: Alkalojdi tal-ergotina (e.ż., ergotamine u dihydroergotamine) [sustratti ta' CYP3A4]
English: Vinca Alkaloids (e.g., vincristine and vinblastine) [CYP3A4 substrates]
Maltese: Alkalojdi Vinca (e.ż., vincristine u vinblastine) [sustratti ta' CYP3A4]
English: In an independent published study, Alfentanil AUC0-  6-fold
Maltese: Fi studju indipendenti ppublikat, Alfentanil AUC0-  6 darbiet
English: In an independent published study, Fentanyl AUC0-  1.34-fold
Maltese: Fi studju indipendenti ppublikat, Fentanyl AUC0-  1.34 darbiet
English: Ciclosporin (in stable renal transplant recipients receiving chronic ciclosporin therapy)
Maltese: Ciclosporin (f'riċevituri stabbli ta' trapjant tal-kliewi li qed jirċievu terapija kronika b'ciclosporin)
English: Carbamazepine and long-acting barbiturates (e.g., phenobarbital, mephobarbital) [potent CYP450 inducers]
Maltese: Carbamazepine u barbiturates li jaħdmu fit-tul (e.ż., phenobarbital, mephobarbital) [indutturi qawwijin ta' CYP450]